Edwards Lifesciences (EW) could possibly be a strong alternative for buyers given the corporate's r
Edwards Lifesciences (EW) could possibly be a strong alternative for buyers given the corporate’s remarkably enhancing earnings outlook. Whereas the inventory has been a powerful performer currently, this pattern may proceed since analysts are nonetheless elevating their earnings estimates for the corporate.
The upward pattern in estimate revisions for this medical system maker displays rising optimism of analysts on its earnings prospects, which ought to get mirrored in its inventory worth. In spite of everything, empirical analysis exhibits a powerful correlation between tendencies in earnings estimate revisions and near-term inventory worth actions. Our inventory score device — the Zacks Rank — has this perception at its core.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Sturdy Purchase) to a Zacks Rank #5 (Sturdy Promote), has a formidable externally-audited track record of outperformance, with Zacks #1 Ranked shares producing a mean annual return of +25% since 2008.
For Edwards Lifesciences, there was sturdy settlement among the many masking analysts in elevating earnings estimates, which has helped push consensus estimates significantly…